NIH-Funded Rat-Study Indicates ChromeMate® Reduces Vascular Inflammation

San Francisco, Calif. – June 9, 2008 – A new research study shows that ChromeMate®, InterHealth Nutraceuticals’ patented niacin-bound chromium complex, significantly reduces vascular inflammation, while in this study, chromium picolinate did not. Reduction of vascular inflammation can decrease the risk of cardiovascular disease, which is closely linked with diabetes. The study, presented today at the American Diabetes Association’s 68th Annual Scientific Session, was funded by the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH).

The eight-week study looked at blood markers for vascular inflammation including TNF-α, MCP-1, retinol binding protein-4 (RBP-4), cholesterol, and triglycerides in obese Zucker diabetic rats. The diets of test animals were supplemented with 400 micrograms of chromium (III) from ChromeMate® or chromium picolinate per kilogram of body weight.

When compared with animals in the control group, the ChromeMate® group experienced significantly lower total cholesterol and triglycerides than the group supplemented with chromium picolinate. Levels of TNF-α, MCP-1, RBP-4 were also lower in the ChromeMate® group than the control group, while the chromium picolinate group did not experience any reduction in those markers.

“Results of this study further confirm a comprehensive body of evidence that demonstrates the cardiovascular benefits of ChromeMate®,” stated InterHealth CEO Paul Dijkstra. “ChromeMate® is also highly effective in helping maintain healthy blood sugar levels and body weight, which is important for people with diabetes. Given the close link between diabetes and cardiovascular disease, ChromeMate® represents a triple benefit in promoting good health.”

Research results were presented at the American Diabetes Association’s 68th Annual Scientific Sessions, June 6-10th in San Francisco. The conference was attended by 13,000 top scientists, physicians and other health care professionals from around the world who shared cutting-edge research, treatment recommendations and advances toward a cure for diabetes.

About ChromeMate®
ChromeMate® (generically known as niacin-bound chromium, chromium nicotinate or chromium polynicotinate) is a patented, oxygen-coordinated chromium complex that plays an important role in regulating insulin function, maintenance of healthy blood sugar and cholesterol levels, normal energy production, and the promotion of healthy body weight. Shown to be 18-times more bioactive than other types of niacin-bound chromium, it is GRAS (Generally Recognized as Safe) affirmed and is an ideal ingredient for dietary supplements and functional foods and beverages.

About InterHealth Nutraceuticals, Inc.
InterHealth Nutraceuticals researches, develops, markets and distributes specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. In addition to ChromeMate®, the company’s products include Super CitriMax®, which is also GRAS-affirmed, Aller-7®, OptiBerry®, UC-II®, L-OptiZinc®, Protykin® and ZMA®. For more information about InterHealth and its products, call 1-800-783-4636 or 1-707-751-2800 (outside U.S.) or visit the website at

# # #

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.